Novartis NewsNovartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer arcticnovartis
Late-breaking NATALEE subgroup analysis to be presented at ESMO shows invasive disease-free survival (iDFS) benefit remains consistent in all subgroups, including in patients with stage II tumors, node-negative disease and those who are 65 or older1
http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00arcticnovartishttp://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngarcticnovartis2023-10-20 12:04:032023-10-20 12:04:03Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
Novartis NewsNovartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer arcticnovartis
Late-breaking NATALEE subgroup analysis to be presented at ESMO shows invasive disease-free survival (iDFS) benefit remains consistent in all subgroups, including in patients with stage II tumors, node-negative disease and those who are 65 or older1
http://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00arcticnovartishttp://www.pharmastrategies.org/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngarcticnovartis2023-10-20 12:03:242023-10-20 12:03:24Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
